Skip to main content

Building Related Illness (BRI)/ Sick Building Syndrome (SBS)

BayBiotech.NET
Built environments both residential and non residential are subject to number of indoor air quality (IAQ) and Indoor environment (IE) problems that may cause acute symptoms, health risks or discomfort.
A frequent IAQ and IE investigations can determine the occurrence of BRI and provide with healthier work environment. This is of utmost importance for Pharmaceutical/ Life Sciences industry where the product is directly subject to the human usage.
Non residential buildings are more prone to BRI as there is a high volume of occupants coming from diverse geographical areas interact in an environment where the ventilation of the building is not directly under the occupants control.
Health hazard evaluation teams from the National Institute of Occupational Safety and Health (NIOSH) conducts the investigation upon request and provides with strategies to avoid the recurrence of the problem. Some of the risk factors that may be used to evaluate biological contaminants as potential causes of allergy/asthma/sinusitis are as follows:
1. Mold: active mold infestation on building material, building history of water damage, wet building site, musty odors, viable mold test results of >1000 CFU/m3 and total mold counts >10,000 S/m3.
2. Dust mites: damp interiors, > 2 ug/g mite allergen levels in floor dust samples.
3. Apart from dust mites and mold, bacterias are major contributors to indoor health hazards and some of the diseases caused due to them are Tuberculosis, Pneumonia, Diphtheria, Anthrax, Meningitis, Respiratory infections and wound infections.

Poor IAQ contributed by various identifiable factors may cause decreased work performance and may impose significant economic costs on employers. Thus, it is important to have a regular investigations planned to test the health of the buildings used for performing the work.

In the US, NIOSH has developed a protocol to serve the needs of its health hazard evaluation teams. Such a team consists of an industrial hygienist, an epidemiologist, and a technical person familiar with the operation and maintenance of building mechanical systems.

To find out more on the topic, you may want to follow the readings as under:

1. www.epa.gov
2. USEPA/ NIOSH, EPA/400/1-91/003, DHHS Publication No. 91-1141-1991.
3. Thad Godish, Indoor Environmental Quality, CRC Press LLC, 2001.

Comments

Popular posts from this blog

Amendments for High Risk Device Type Regulatory Pathway

BayBiotech.NET Government Accounting Office (“GAO”) has issued a long-awaited report evaluating the use of the 510(k) process by the Food and Drug Administration (“FDA” or the “Agency”) in the January of 2009. Report mainly focused on Preamendment class III devices. Although most high-risk class III medical devices are subject to the demanding premarket approval (“PMA”) process, preamendment class III devices may be cleared through the 510(k) pathway until FDA issues regulations requiring a PMA. Under the Safe Medical Devices Act of 1990, FDA was required either to reclassify preamendment class III devices into class I or II, or (2) issue regulations requiring PMA approval for the devices, GAO noted that 20 preamendment class III device types have not yet been addressed by the Agency. GAO has urged FDA to take required steps to address the remaining class III devices that continue to be eligible for 510(k) review. As a result of the report, FDA has committed to address al...

Risk Based Clinical Monitoring

BayBiotech.NET FDA's recommendation of Risk Based Monitoring of Clinical Trials , as published in their Draft Guidance in August 2011. For the first time, FDA provided guidance on monitoring of clinical investigations in 1988 which was recently withdrawn, stated that the “most effective way” to monitor an investigation was to “maintain personal contact between the monitor and the investigator throughout the clinical investigation.” At the time the guidance was issued, sponsors had only limited ways to effect meaningful communication with investigators other than through on-site visits.   This guidance recommends an assessment by the sponsor for the need of 100% on-site monitoring. Such an assessment may be based on the complexity of the study protocol and not be generally applicable to all trial types. It explains the importance of remote monitoring facilitated by the use of electronic data capture system (EDC) and also emphasizes the need of the identifying crit...

eCTD Submission Specifications

BayBiotech.NET The electronic Common Technical Document (eCTD) is an interface for the pharmaceutical industry to agency transfer of regulatory information. eCTD technical document format development was done by International Conference on Harmonization (ICH) Multidisciplinary Group 2 Expert Working Group (ICH M2 EWG). Details on the specification for the ICH eCTD can be found in the guidance document M2 eCTD: Electronic Common Technical Document Specification. Currently, eCTD is the preferred format for electronic submissions by U.S. Food and Drug Administration. Although originally the CTD and the eCTD were designed for marketing applications, they could apply equally to other submission types, including INDs, master files, advertising material, and promotional labeling. In June 2008, FDA has issued guidelines for organizing the electronic regulatory document filing using the eCTD tools. This guidance discusses issues related to the electronic submission of applications for hum...